ABBV vs MEDP: fair value comparison
AbbVie Inc. and Medpace Holdings, Inc. · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ABBV currently sits closer to the top of our ranking by discount to fair value.
| ABBV | MEDP | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $276.47 | $618.47 |
| 12-month range | $197.38–$285.42 | $393.42–$630.19 |
| Rank by discount to fair value | #78 of 108 Healthcare | #79 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | Strong |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: ABBV fair value analysis · MEDP fair value analysis